Third Generation Heart Valve Improves Flow, Survival
February 11, 2008 - Leman Cardiovascular’s animal studies to evaluate the performance in both the aortic and mitral positions of its heart valve resulted in energy loss in blood cardiac throughput and a 100 percent survival rate at 90 days, an approach that may rival stented valves.
The LCV heart valve is designed to maximize blood flow and is said to require less work to accommodate any given cardiac output. The internal supports are placed in a manner to achieve a restoration of the native anatomy at the inflow of the valve; this allows the stress-free preserved leaflets to function in a manner mimetic of a natural valve. The new data shows that animals in which the LCV valve was implanted show an average of 120 percent increase in hemodynamic studies over existing stented valves.
"The animal study results are really very encouraging and show the product holds strong promise," said Professor R. Bianco, head of the Experimental Surgical Department of the University of Minnesota. Professor Bianco has no conflict of interest with Leman
For more information: www.lemancardiovascular.com and www.hancockjaffe.com
More like this
- St. Jude Medical Announces First Enrollment in Anti-Clotting Study
- New Surgical Valve Receives CE Mark Approval
- Favorable Results Presented on Edwards’ Mitral Valve Repair Ring
- St. Jude Medical Announces Publication of 20-year Durability in Aortic, Mitral Stented Tissue Valves
- SCAI Highlights Advances in Percutaneous Valve Therapy